ACTU (ACTU) COO granted 105,000 long-term stock options at $2.49 strike

Rhea-AI Filing Summary

ACTUATE THERAPEUTICS, INC. reported that Chief Operating Officer Andrew Paul Mazar received an employee stock option grant for 105,000 options to buy common stock at an exercise price of $2.49 per share.

The options expire on April 1, 2036. According to the vesting terms, 25% of the grant will vest on April 1, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months. After this grant, he holds 105,000 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Mazar Andrew Paul

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	105,000	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 105,000 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 105,000 options Exercise price: $2.49 per share Expiration date: April 1, 2036 +4 more

7 metrics

Options granted 105,000 options Employee stock option grant to COO on April 1, 2026

Exercise price $2.49 per share Strike price of employee stock options

Expiration date April 1, 2036 Option term end date

Underlying shares 105,000 shares Common stock underlying granted options

Post-grant derivative holdings 105,000 options Total derivative securities owned following transaction

Initial vesting date April 1, 2027 25% of options vest on this date

Remaining vesting period 36 months Remaining 75% vests in equal monthly installments

Key Terms

Employee Stock Option, underlying security, exercise price, vesting, +1 more

5 terms

Employee Stock Option financial

"Employee Stock Option (right to buy)"

An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.

underlying security financial

"underlying_security_title": "Common Stock""

exercise price financial

"conversion_or_exercise_price": "2.4900""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"Options will vest as to 25% on April 1, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

derivative securities financial

"derivativeTransactionCount": 1"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mazar Andrew Paul

(Last) (First) (Middle)

C/O ACTUATE THERAPEUTICS, INC.

1751 RIVER RUN, SUITE 400

(Street)

FORT WORTH TEXAS 76107

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ACTUATE THERAPEUTICS, INC. [ ACTU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$2.49	04/01/2026		A		105,000		(1)	04/01/2036	Common Stock	105,000	$0	105,000	D

Explanation of Responses:

1. Options will vest as to 25% on April 1, 2027 with the remaining 75% vesting in equal monthly installments during the 36 months following the first anniversary of the grant date.

	/s/ Paul Lytle, Attorney-in-Fact	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did ACTU (Actuate Therapeutics) disclose about Andrew Mazar in this Form 4?

ACTUATE THERAPEUTICS disclosed that Chief Operating Officer Andrew Paul Mazar received a grant of 105,000 employee stock options. These options give him the right to buy common shares at $2.49 each, subject to a multi-year vesting schedule and an expiration date in April 2036.

How many stock options did ACTU COO Andrew Mazar receive?

Andrew Paul Mazar received 105,000 employee stock options from ACTUATE THERAPEUTICS. Each option is a right to buy one share of common stock at a fixed $2.49 exercise price, providing long-term equity-based compensation tied to the company’s future stock performance.

What is the exercise price and expiration date of Andrew Mazar’s ACTU options?

The stock options granted to Andrew Paul Mazar have an exercise price of $2.49 per share and expire on April 1, 2036. This long-dated term allows substantial time for potential value realization if the company’s share price exceeds the exercise price.

How do Andrew Mazar’s ACTU stock options vest over time?

The options vest 25% on April 1, 2027, with the remaining 75% vesting in equal monthly installments over the next 36 months. This structure encourages long-term retention by linking most of the award to continued service after the initial cliff-vesting date.

Did Andrew Mazar buy or sell any ACTU common stock in this Form 4?

The Form 4 shows a grant of derivative securities, not an open-market trade in ACTU common stock. Andrew Paul Mazar received 105,000 employee stock options as a compensation award; there were no reported common-share purchases or sales in this filing.

How many derivative securities does Andrew Mazar hold after this ACTU option grant?

After the reported transaction, Andrew Paul Mazar beneficially owns 105,000 derivative securities directly. These consist of employee stock options linked to ACTU common stock, all at a $2.49 exercise price, subject to the specified vesting schedule and 2036 expiration date.